Clinical Trial Update: Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial compared AZD6244 (selumetinib) plus dacarbazine versus dacarbazine alone in patients with BRAF mutation-positive melanoma; results from the comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• AZD6244 (selumetinib) (selumetinib)
• Dacarbazine (dacarbazine)

Snippet

Sponsor: AstraZeneca | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2015-12-09